Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2020-06-01 Director's Dealing
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-06-01 English
FORM 4
Director's Dealing
2020-05-29 English
SC 13D/A
Major Shareholding Notification
2020-05-29 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a material definitive agreement (an underwriting agreement for a secondary offering), a stock repurchase agreement, an amendment to an investor agreement, and a bridge loan facility. These are all related to financing activities and capital structure changes. The document is not a full financial report but an announcement of significant financing transactions and agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement of a report but a substantive filing about financing events.
2020-05-29 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3) related to a public offering of common stock by selling shareholders. It includes detailed information about the offering, underwriting, share amounts, pricing, and related legal disclaimers. The document references the Securities Act of 1933 and SEC rules, and it is clearly a registration and offering document rather than a financial report or earnings release. The presence of terms like 'prospectus supplement,' 'selling shareholders,' 'underwriting discount,' and 'offering price' indicates this is a capital markets filing related to financing activities. Therefore, the document fits the category of Capital/Financing Update (CAP).
2020-05-28 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(3) related to a public offering of common stock by Regeneron Pharmaceuticals, Inc. It includes detailed information about the offering, selling shareholders, underwriting, and related financial terms. The document references SEC registration numbers and includes disclaimers typical of securities offering documents. It is not a financial report, earnings release, or management discussion, but rather a capital markets document related to a share offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief notice, confirming it is a full financing update document rather than a simple announcement (RPA) or regulatory filing (RNS).
2020-05-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.